We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+5.04%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.97B
AUM Growth
-$106M
Cap. Flow
-$271M
Cap. Flow %
-3.88%
Top 10 Hldgs %
34.81%
Holding
187
New
15
Increased
42
Reduced
87
Closed
11

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$28.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$26.8M
3
EXAS
Exact Sciences
EXAS
+$15.3M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$13.7M
5
CRL icon
Charles River Laboratories
CRL
+$6.89M

Top Sells

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$91.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$38.7M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$24M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$19.3M
5
AXSM icon
Axsome Therapeutics
AXSM
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 99.34%
2 Industrials 0.59%
3 Energy 0.02%
4 Communication Services 0.01%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTEM
101
DELISTED
Molecular Templates, Inc.
MTEM
$8.46M 0.12%
751,867
– –
BDTX icon
102
Black Diamond Therapeutics
BDTX
$103M
$7.97M 0.11%
4,717,113
– –
BIIB icon
103
Biogen
BIIB
$30.4B
$7.67M 0.11%
28,735
+6,885
+32% +$1.46M
TXG icon
104
10x Genomics
TXG
$5.55B
$7.24M 0.1%
254,134
-5,237
-2% -$200K
AMWL icon
105
American Well
AMWL
$221M
$6.35M 0.09%
88,485
– –
TFX icon
106
Teleflex
TFX
$5.96B
$6.34M 0.09%
31,480
-64,504
-67% -$15.4M
GILD icon
107
Gilead Sciences
GILD
$167B
$6.04M 0.09%
97,854
+22,428
+30% +$1.41M
SGEN
108
DELISTED
Seagen Inc. Common Stock
SGEN
$5.87M 0.08%
42,926
-6,450
-13% -$1.05M
DOCS icon
109
Doximity
DOCS
$3.87B
$5.85M 0.08%
193,439
+57,117
+42% +$2.09M
JNJ icon
110
Johnson & Johnson
JNJ
$609B
$5.01M 0.07%
30,671
+1,757
+6% +$297K
BMRN icon
111
BioMarin Pharmaceuticals
BMRN
$11.5B
$4.54M 0.07%
53,493
-20,260
-27% -$1.8M
SUPN icon
112
Supernus Pharmaceuticals
SUPN
$2.79B
$4.04M 0.06%
119,278
+36,878
+45% +$1.2M
CYTK icon
113
Cytokinetics
CYTK
$10.9B
$3.45M 0.05%
71,200
+4,800
+7% +$231K
GH icon
114
Guardant Health
GH
$20.7B
$3.34M 0.05%
62,083
-8,497
-12% -$436K
LLY icon
115
Eli Lilly
LLY
$1.05T
$3.07M 0.04%
9,490
+8,521
+879% +$2.7M
LUNG icon
116
Pulmonx
LUNG
$59.1M
$2.89M 0.04%
173,336
– –
OLK
117
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$2.8M 0.04%
230,522
-4,751
-2% -$72.8K
QTTB icon
118
Q32 Bio
QTTB
$346M
$2.61M 0.04%
90,140
– –
AZN icon
119
AstraZeneca
AZN
$262B
$2.46M 0.04%
22,200
-21,300
-49% -$2.7M
BCYC
120
Bicycle Therapeutics
BCYC
$294M
$2.28M 0.03%
98,100
+13,700
+16% +$326K
ABBV icon
121
AbbVie
ABBV
$450B
$2.28M 0.03%
16,997
+16,189
+2,004% +$2.32M
RCUS icon
122
Arcus Biosciences
RCUS
$3.44B
$2.18M 0.03%
83,500
-6,600
-7% -$175K
RLMD icon
123
Relmada Therapeutics
RLMD
$550M
$1.97M 0.03%
53,187
+18,187
+52% +$504K
SGHT icon
124
Sight Sciences
SGHT
$274M
$1.87M 0.03%
294,606
– –
NTLA icon
125
Intellia Therapeutics
NTLA
$1.59B
$1.71M 0.02%
30,478
+14,684
+93% +$911K
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2022 Portfolio in Review

As of Q3 2022, Bellevue Group held 187 positions worth $6.97B, down 1.5% from $7.07B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group withdrew a net $271M in Q3 2022, closing 11 positions and reducing 87 holdings. Its most notable exit was Radius Health, Inc., an estimated $91.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Zai Lab worth $1.28M.

  • Bellevue Group's largest Q3 2022 buy was Zai Lab: 36,600 shares worth $1.28M.
  • Bellevue Group added most to Revolution Medicines in Q3 2022, an estimated $28.5M increase.
  • Bellevue Group's biggest Q3 2022 reduction was Sarepta Therapeutics, cutting an estimated $38.7M.
  • Bellevue Group fully exited Radius Health, Inc. in Q3 2022, selling an estimated $91.2M.
  • Bellevue Group's ten largest holdings make up 35% of its $6.97B portfolio in Q3 2022.
  • Bellevue Group opened 15 new positions and closed 11 in Q3 2022.
  • Bellevue Group's portfolio value fell 1.5% quarter-over-quarter to $6.97B.

Based on Bellevue Group's 13F filing for Q3 2022, filed 14 Nov 2022.